April 29th 2024
Enhertu, a HER2-directed antibody-drug conjugate, showed a clinically meaningful survival benefit in progression-free survival among patients with HR-positive, HER2-low metastatic breast cancer.
Merck Launches Pivotal Phase III Trials of Novel Drugs for Oncologic, Hematologic Malignancies
January 5th 2024Merck is actively enrolling patients for investigational drugs that treat essential thrombocythemia, chronic lymphocytic leukemia, small lymphocytic lymphoma, non-small cell lung cancer, endometrial carcinoma, and metastatic castration-resistant prostate cancer.
Results of RUBY Trial Show Improved Survival With Jemperli Plus Zejula in Endometrial Cancer
December 18th 2023Phase III RUBY/ENGOT-EN6/GOG3031/NSGO trial show a statistically significant and clinically meaningful benefit for Jemperli plus standard-of-care chemotherapy with carboplatin and paclitaxel, followed by Jemperli plus Zejula across the overall patient population and among a subpopulation of patients with MMRp/MSS tumors in those with primary advanced or recurrent endometrial cancer.
FDA Approves Keytruda Plus Chemotherapy for Biliary Tract Cancer
November 1st 2023The approval of pembrolizumab (Keytruda; Merck) combined with gemcitabine and cisplatin for the treatment locally advanced unresectable or metastatic biliary tract cancer is the sixth sixth indication for the anti-PD-1 therapy for gastrointestinal cancers.
Pandemic-Proof Clinical Study Start-Up
December 10th 2020The fear of exposure to SARS-CoV-2 in healthcare settings has deterred people from seeking care for non-COVID-19 diseases. One solution to patient care and biomedical research disruptions is implementing remote solutions for conducting research and collecting samples.